Michael Rosenblum, MD, PhD

Michael Rosenblum, MD, PhD, is a Professor of Dermatology and Vice Chair of Research in the Department of Dermatology at the University of California, San Francisco (UCSF) and is one of the world’s leading skin immunologists. Dr. Rosenblum’s research focuses on understanding the fundamental mechanisms of how immune responses are regulated in tissues, and how this knowledge can be exploited to treat human disease. He recently helped to generate and validate a novel therapeutic molecule that selectively activates human regulatory T cells, taken into clinical trials in patients with autoimmune diseases.

Dr. Rosenblum is a recipient of the Burroughs Wellcome Fund Career Award for Medical Scientists, the NIH Director’s New Innovator Award, the Dermatology Foundation’s Charles & Daneen Stiefel Scholar Award in Autoimmune & Connective Tissue Diseases, as well as multiple NIH R01 & R21 awards. Most recently, he was named the William Montagna Lecturer by the Society for Investigative Dermatology. He has authored over 85 basic science research papers. He is a co-founder of TRex Bio and Sitryx Bio as well as a Scientific Co-founder of Delinia Bio, which was sold to Celgene in 2017.

He received his medical degree and PhD in immunology from the Medical College of Wisconsin. He completed his dermatology residency training at UCSF in the prestigious Physician-Scientist Training Pathway before joining the UCSF faculty in 2012.